Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-

Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Deve

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnol

Aldeyra Therapeutics NASDAQ: ALDX Chief Executive Todd Brady said the company expects near-term feed

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnol

New York, New York--(Newsfile Corp. - May 29, 2026) - Bronstein, Gewirtz & Grossman, LLC, a national

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, reminds investors o

[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potent

LOS ANGELES--(BUSINESS WIRE)---- $ALDX--ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics

New York, New York--(Newsfile Corp. - May 29, 2026) - WHY: Rosen Law Firm, a global investor rights

NEW YORK--(BUSINESS WIRE)---- $ALDX #ALDX--Faruqi & Faruqi, LLP, a leading national securities law f

NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareho

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff

NEW YORK, May 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, remin

NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, r

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been

LOS ANGELES, May 28, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights li

New York, New York--(Newsfile Corp. - May 27, 2026) - WHY: Rosen Law Firm, a global investor rights

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogniz

Aldeyra stock plunges after FDA rejects its dry eye drug reproxalap, raising concerns over efficacy

Analysts downgraded CF, ALDX, TTD, TME and DUOL. Check their ratings and price targets. Interested i

HC Wainwright & Co. analyst Matthew Caufield downgrades Aldeyra Therapeutics (NASDAQ:ALDX) fr

Aldeyra stock crashes 68% after the FDA rejects its dry eye drug, reproxalap, for the third time. Ge

US stocks rose, with Dow Jones up 0.39% & NASDAQ up 0.59%. Energy shares jumped 1.7%, while indu

US stocks started higher this morning, with NASDAQ up over 100 points. Energy shares rose by 1.3%, w

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering a

FDA extends Aldeyra's reproxalap PDUFA date to March 2026 after a major NDA amendment tied to ne

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering a

BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintain

4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improvin

The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the European Medicines Agenc

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Admin

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering a

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) wi

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and confer

BTIG analyst Thomas Shrader maintains Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and lowers th

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) wi